Zevra Therapeutics Q2 revenue rises 53% on MIPLYFFA sales
ZVRA•Analyst coverage
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
- The average consensus recommendation for the pharmaceuticals peer group is "buy"
- Wall Street's median 12-month price target for Zevra Therapeutics Inc is $24.50, about 132.9% above its August 4 closing price of $10.52
- The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 12 three months ago
Key financial details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Beat | $39.66 mln | $33.88 mln (9 Analysts) |
| Q2 Net Income | $8.75 mln | ||
| Q2 Income from Operations | $16.78 mln | ||
| Q2 Operating Expenses | -$21.05 mln | ||
| Q2 Pretax Profit | $12.79 mln |
Outlook and development plans
- Company expects to continue engagement with the FDA on celiprolol development in H2 2026
- Company says available financial resources are sufficient to execute on strategic priorities
Related News
Genco Shipping Q2 net income returns to profit at $16.65 million; revenue rises 68.53% YoY to $136.41 million
GNK•
Morningstar Executive Chairman Joseph Mansueto disposes of USD 2.75 million in common shares
MORN•
